1. Home
  2. BLTE vs DSGX Comparison

BLTE vs DSGX Comparison

Compare BLTE & DSGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Belite Bio Inc

BLTE

Belite Bio Inc

HOLD

Current Price

$146.23

Market Cap

6.2B

Sector

Health Care

ML Signal

HOLD

Logo Descartes Systems Group Inc. (The)

DSGX

Descartes Systems Group Inc. (The)

HOLD

Current Price

$70.76

Market Cap

6.2B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
BLTE
DSGX
Founded
2018
1981
Country
United States
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
6.2B
6.2B
IPO Year
2021
1999

Fundamental Metrics

Financial Performance
Metric
BLTE
DSGX
Price
$146.23
$70.76
Analyst Decision
Strong Buy
Buy
Analyst Count
7
9
Target Price
$198.00
$105.22
AVG Volume (30 Days)
215.5K
505.5K
Earning Date
05-08-2026
06-03-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$12.05
Revenue Next Year
$492.11
N/A
P/E Ratio
N/A
$37.05
Revenue Growth
N/A
N/A
52 Week Low
$56.68
$62.56
52 Week High
$200.00
$108.51

Technical Indicators

Market Signals
Indicator
BLTE
DSGX
Relative Strength Index (RSI) 51.55 44.15
Support Level $130.00 $69.44
Resistance Level $168.44 $74.57
Average True Range (ATR) 8.61 3.20
MACD 1.00 -0.53
Stochastic Oscillator 75.20 7.88

Price Performance

Historical Comparison
BLTE
DSGX

About BLTE Belite Bio Inc

Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.

About DSGX Descartes Systems Group Inc. (The)

Descartes Systems Group provides a software solution that allows users in the shipping industry to communicate with one another. Its core product is the Global Logistics Network, which is best understood as transaction-driven. Descartes charges clients to send/receive messages, data, and documents on the GLN. Customers typically contract for a monthly minimum over a multiyear period. The GLN platform allows Descartes to upsell additional software modules as well, typically provided via a software-as-a-service model.

Share on Social Networks: